Status:
RECRUITING
Effect of Nasal Spray Dexmedetomidine on Emergence Delirium Prevention in Total Hip Replacement
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Delirium
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
Emergence Delirium (ED) is a common postoperative complication refers to an acute brain dysfunction that occurs during the recovery from general anesthesia, which is mainly characterized by sudden att...
Detailed Description
The incidence of hip fracture after surgery in patients over 55 years old is about 45%, and ED is highly predictive of delirium during postoperative hospitalization, which occurs in about 1/3 of ED pa...
Eligibility Criteria
Inclusion
- Age ≥60 years old
- Total hip arthroplasty under general anesthesia
- ASA II-III
- Informed consent was obtained from patients or their guardians
Exclusion
- Allergy or contraindication to dexmedetomidine
- Severe rhinitis and nasal deformity
- Severe bradycardia (heart rate \<50 beats/minute) or atrioventricular block of grade 2 or higher, permanent pacemaker implantation, severe heart failure or ejection fraction \<30%
- Patients with previous myocardial infarction, unstable angina pectoris, severe arrhythmia, and cardiac insufficiency
- Emergency surgery
- Severe hepatic and renal dysfunction (Child-Pugh class B and C, CKD3-5)
- Preoperative mental illness, cognitive impairment, and communication difficulties could not be evaluated in the study
- Preoperative delirium was present
Key Trial Info
Start Date :
November 21 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 8 2025
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT06579001
Start Date
November 21 2024
End Date
April 8 2025
Last Update
January 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
闗闗
Hangzhou, China